Neuland Laboratories schedules analyst meetings in Hyderabad

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Neuland Laboratories schedules group investor meetings on September 15 and 17, 2026
  • Events include Emkay Global Investors Meeting and ICICI Securities Healthcare Day
  • Both meetings will be held in Hyderabad
  • Schedule is subject to change per SEBI Regulation 30 disclosure
powered bylight_fuzz_icon
50506517

*this image is generated using AI for illustrative purposes only.

Neuland Laboratories Limited has scheduled two group meetings with analysts and institutional investors in Hyderabad later this month.

The company issued the intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule is subject to change based on participant availability.

Meeting Schedule

The management team will participate in the following events:

Date Event Name Location Type
September 15, 2026 Emkay Global Investors Meeting Hyderabad Group meet
September 17, 2026 ICICI Securities - Hyderabad Healthcare Day Hyderabad Group meet

Sarada Bhamidipati, Company Secretary, signed the disclosure dated September 9, 2026.

Historical Stock Returns for Neuland Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.11%+2.82%+5.94%+86.83%+58.99%0.0%

What specific strategic initiatives or pipeline developments is Neuland Laboratories likely to highlight during the Hyderabad Healthcare Day?

How might investor sentiment from these group meetings influence Neuland's stock valuation in the short term?

Are there any upcoming regulatory approvals or clinical trial results for Neuland's key products that investors will be pressing management on?

Neuland Laboratories approves ₹126 crore Kakinada land purchase

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Neuland Laboratories approved ₹126 crore capex for 134 acres in Kakinada
  • Funding will come entirely from internal accruals
  • Company holds right of first refusal for additional 66 acres
  • Total potential land parcel size reaches approximately 200 acres
  • Board approved the move on September 7, 2026
powered bylight_fuzz_icon
50333403

*this image is generated using AI for illustrative purposes only.

Neuland Laboratories approved ₹126 crore in capital expenditure on September 7, 2026, to acquire approximately 134 acres of land in Kakinada, Andhra Pradesh. The board authorized the purchase at Auro Industrial City to support the company’s future expansion plans.

The expenditure will be financed entirely through internal accruals. The company also secured a right of first refusal to purchase an additional contiguous parcel of approximately 66 acres. This option would bring the potential aggregate land holding at the site to approximately 200 acres.

Investment Details

The board meeting held on September 7, 2026, formalized the capital allocation. The transaction falls under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Parameter Detail
Investment Amount ₹126 crore
Land Area Approximately 134 acres
Location Auro Industrial City, Kakinada
Financing Mode Internal accruals
Additional Option Right of first refusal for 66 acres

What the Numbers Show

The decision to fund a ₹126 crore land acquisition solely through internal accruals signals strong cash generation capacity. By avoiding external debt for this strategic asset purchase, the company preserves its balance sheet flexibility for future operational expenditures or capacity additions.

Historical Stock Returns for Neuland Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.11%+2.82%+5.94%+86.83%+58.99%0.0%

What specific pharmaceutical or agrochemical production facilities does Neuland Laboratories plan to construct on the 134-acre site in Kakinada?

How might the company's decision to use internal accruals rather than debt impact its future dividend policy or share buyback capabilities?

What is the estimated timeline for operational readiness of the new facility, and how will it affect the company's capacity utilization rates in the coming fiscal years?

More News on Neuland Laboratories

1 Year Returns:+58.99%